Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia
Biochemical Pharmacology · 2024-02 · 220 · 115985
DOI: 10.1016/j.bcp.2023.115985 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2024-02. Verfasst von Megan Yu Cai Lim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore. Hauptthemen laut MEDLINE: Hypercholesterolemia. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 116 Literaturangaben. Gefördert von: National University of Singapore.
Abstract (Originalsprache)
Despite the availability of many therapeutic options, the prevalence of hypercholesterolemia remains high. There exists a significant unmet medical need for novel drugs and/or treatment combinations to effectively combat hypercholesterolemia while minimizing adverse reactions. The modulation of cholesterol 7α-hydroxylase (CYP7A1) expression via perturbation of the farnesoid X receptor (FXR) - dependent pathways, primarily FXR/small heterodimer partner (SHP) and FXR/ fibroblast growth factor (FGF)-19/ fibroblast growth factor receptor (FGFR)-4 pathways, presents as a potential option to lower cholesterol levels. This paper provides a comprehensive review of the important role that CYP7A1 plays in cholesterol homeostasis and how its expression can be exploited to assert differential control of bile acid synthesis and cholesterol metabolism. Additionally, the paper also summarizes the current therapeutic options for hypercholesterolemia, and positions modulators of CYP7A1 expression, namely FGFR4 inhibitors and FXR antagonists, as emerging and distinct pharmacological agents to complement and diversify the treatment regime. Their mechanistic and clinical considerations are also extensively described to interrogate the benefits and risks associated with using FXR-mediating agents, either singularly or in combination with recognised agents such as statins to target hypercholesterolemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.
- Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore. Electronic address: phahohk@nus.edu.sg.
Förderung
- National University of Singapore
Zitieren
APA
Yu Cai Lim, M., & Kiat Ho, H. (2024). Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia. Biochemical Pharmacology, 220, 115985. https://doi.org/10.1016/j.bcp.2023.115985
Vancouver
Yu Cai Lim M, Kiat Ho H. Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia. Biochemical Pharmacology. 2024;220:115985. doi:10.1016/j.bcp.2023.115985
BibTeX
@article{YuCaiLim2024,
author = {Yu Cai Lim, Megan and Kiat Ho, Han},
title = {Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia},
journal = {Biochemical Pharmacology},
year = {2024},
volume = {220},
pages = {115985},
doi = {10.1016/j.bcp.2023.115985}
}
EUVIMED